247marketnews Editorial Watchlist November 10, 2026

Co-Diagnostics (CODX) reports earnings tonight. NFT Limited (MI) has 80.93M shares outstanding, with a pilot target for Q1 2027. Vivakor (VIVK) retired $15.2M in convertible notes, and Kraig Biocraft Labs (KRA) reported a 30%+ production increase and first commercial spider silk shipment.

Original reporting
Published Nov 10, 2026, 5:48 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 11, 2026, 3:21 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefFinancial news
Primary signal
$MI
Neutral
medium confidence
Mentioned
$MI · $CODX · $VIVK
Relevance
4/10
AlphAI data visualization · based on quantisnow.com
Decision brief

The 30-second read

$MINeutralLow
01

Why it matters

Provides a concise snapshot of upcoming events but no new financial data or material disclosures.

02

Market read

Low‑to‑moderate relevance for traders focused on micro‑cap biotech; no immediate actionable catalyst.

03

What to watch

Potential supply‑chain or regulatory hurdles for spider‑silk production are not discussed.

Relevance 4/10Novelty 2/10Timing: today

Background

The article is a watchlist roundup summarizing upcoming catalysts for four micro‑cap biotech and diagnostics companies.

Company-level read

Ticker impact

$MINeutralMedium confidence
Context

NFT Limited appears in the watchlist with upcoming pilot target and share snapshot, indicating upcoming catalyst.

Expected impact

likely limited pressure pending further data releases

Evidence & confidence

The article only lists upcoming milestones without new results.

$CODXNeutralMedium confidence
Context

Co‑Diagnostics is scheduled to report earnings tonight, making it the primary upcoming event.

Expected impact

possible pre‑market movement as traders position for the release

Evidence & confidence

No earnings numbers are provided; only the schedule is new.

$VIVKNeutralMedium confidence
Context

Vivakor retired convertible notes worth $15.2 million and converted the final balance to common shares, a dilution event.

Expected impact

slight downward pressure from dilution

Evidence & confidence

The article reports the conversion but no valuation impact.

Market effects

Limited impact on biotech and diagnostics sectors; highlights ongoing R&D progress.

US‑focused micro‑cap activity; no broader regional effect.

Low; article is a routine watchlist without macro implications.

Counterpoint

The lack of concrete financial results suggests investors may ignore these updates.

Key entities

  • NFT Limited

    Micro‑cap biotech with upcoming pilot target.

  • Co‑Diagnostics

    Diagnostics firm scheduled to report earnings.

  • Vivakor

    Biotech firm retiring convertible notes.

  • Kraig Biocraft Laboratories

    Biotech company with first commercial spider‑silk shipment.

Related articles

$CODXMed

Co-Diagnostics Reports Third Quarter 2026 Financial Results

Co-Diagnostics, Inc. (CODX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Co-Diagnostics Reports Third Quarter 2026 Financial Results Two Regulatory Submissions Under Review in India and the U.S. Third Quarter Operating Expenses Down 12% Year Over Year Platform Capabilities Expanding with ReadyGo Collaboration, India Connectivity and Vecto

$CODXMed

CoSara submits tuberculosis test for India regulatory review

Co-Diagnostics' India joint venture, CoSara, submitted its tuberculosis test for regulatory review in India, reporting 97.3% sensitivity and 96.0% specificity. The test, using Co-Diagnostics' technology, aims for approval by Q4 2026 to begin sales in India and South Asia. India has the highest tuberculosis burden globally, according to the WHO.

$CODXMedAI 8/10

Co-Diagnostics' Joint Venture CoSara Diagnostics Completes Clinical Study and Regulatory Submission for Point-of-Care Tuberculosis Test, Sets Stage for Commercial Launch in India

Co-Diagnostics' joint venture CoSara Diagnostics completed a clinical study for its tuberculosis test, reporting 97.3% sensitivity and 96.0% specificity. The test was submitted to India's CDSCO for regulatory clearance, with a commercial launch anticipated before year-end 2026. The company has also deployed mobile and cloud infrastructure in India to support the launch.

$VIVKMed

Vivakor Completes Direct Midstream Due Diligence, Advancing Proposed $40 Million Acquisition Toward Definitive Agreement

Vivakor, Inc. (VIVK) completed due diligence for a $40M acquisition of Direct Midstream, LLC, which operates 17 saltwater disposal facilities. The deal advances Vivakor's strategy to expand Permian Basin infrastructure and enhance its Remediation Processing Center (RPC) capabilities. The companies are working toward a definitive agreement, subject to final terms and funding.